// App-Quantinova.ai

3080 : OPB-51602: a novel STAT3 inhibitor that targets mitochondrial respiratory chain and triggers STAT3 dependent ROS production

Researchers

Presenter

  • Jayshree L. Hirpara

Principal Investigators

  • Kumi Higuchi

  • Takeshi Tsunoda

  • Boon Cher Goh

  • Shazib Pervaiz

Medical Centers

  • Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

  • Fujii Memorial Research Institute Otsuka Pharmaceutical Co., Ltd, Japan

  • Otsuka Pharmaceutical Co., Ltd, Japan

  • National Univ. of Singapore, Singapore, Singapore.

Locations

  • Japan

  • Singapore

Companies

  • Otsuka Pharmaceutica

  • Otsuka Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

  • Signal transducer and activator of transcription 3

Drug/Treatment

  • 2-deoxyglucose

  • OPB51602

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved